Opinion|Videos|May 22, 2026
Choosing Between Continuous and Fixed Dosing Options in Frontline
Author(s)Andrew H. Lipsky, MD
Six-year data show zanubrutinib remains well tolerated, with rare atrial fibrillation, low bleeding, and no new safety concerns.
Advertisement
Episodes in this series
In the SEQUOIA trial, the BTK inhibitor zanubrutinib was delivered as a continuous dose in frontline chronic lymphocytic leukemia. Andrew H. Lipsky,MD, discusses the potential lifestyle benefits for patients of a continuous dosing approach. He describes BTK monotherapy as the “most simplistic option that we can offer our patients in frontline CLL” at the current time.
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering a scalable model for at-home care.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
During a live event, Seth M. Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice
3
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
4
Opamtistomig Earns FDA Fast Track in First-Line Biliary Tract Cancer
5